Clinical trial
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in…
NCT00186121 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186121 |
|---|---|
| Title | Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women |
| Official title | A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women |
| Lead sponsor | Stanford University, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anastrozole (Arimidex), Goserelin (Zoladex) |
| Enrollment | 35 |
| Start date | Oct 1, 2000 |
| Primary completion | May 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Sep 16, 2005 |
| Last update posted | Oct 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: